Advice
following an abbreviated submission:
insulin aspart (Fiasp®) is accepted for use within NHS Scotland.
Indication under review: treatment of diabetes mellitus in adults.
Insulin aspart (Fiasp®) is a new formulation with a faster onset of action than another formulation of insulin aspart and is available at an equivalent cost.
Download detailed advice58KB (PDF)
Medicine details
- Medicine name:
- insulin aspart (Fiasp)
- SMC ID:
- 1227/17
- Indication:
- Treatment of diabetes mellitus in adults.
- Pharmaceutical company
- Novo Nordisk Ltd
- BNF chapter
- Endocrine system
- Submission type
- Abbreviated
- Status
- Accepted
- Date advice published
- 10 April 2017